
Sign up to save your podcasts
Or
In this episode, we are joined by Andy Yates Ph.D. & Peter O'Brien of Artelo Biosciences. Artelo Biosciences is a clinical-stage company using cutting-edge science to improve patient care. They were founded in 2017 on the promise of therapeutic development based on lipid-signaling modification, including targeting the receptors of the endocannabinoid system. Their aim is to alter the course of treatment for those with a diagnosis of cancer and other serious conditions.
Topics:
1. What are CB1 & CB2 Receptors?
2. Modulating Lipid Signalling Pathways
3. Fatty Acid Binding Proteins
* Twitter - @TheCannabisRev2
* LinkedIn - @thecannabisreview
* Episode Library - https://www.thecannabisreview.ie
+ Artelo Biosciences Inc. https://artelobio.com/
5
33 ratings
In this episode, we are joined by Andy Yates Ph.D. & Peter O'Brien of Artelo Biosciences. Artelo Biosciences is a clinical-stage company using cutting-edge science to improve patient care. They were founded in 2017 on the promise of therapeutic development based on lipid-signaling modification, including targeting the receptors of the endocannabinoid system. Their aim is to alter the course of treatment for those with a diagnosis of cancer and other serious conditions.
Topics:
1. What are CB1 & CB2 Receptors?
2. Modulating Lipid Signalling Pathways
3. Fatty Acid Binding Proteins
* Twitter - @TheCannabisRev2
* LinkedIn - @thecannabisreview
* Episode Library - https://www.thecannabisreview.ie
+ Artelo Biosciences Inc. https://artelobio.com/